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Background and Purpose  The early diagnosis of LMNA-associated muscular dystrophy is 
important for preventing sudden arrest related to cardiac conduction block. However, diag-
nosing early-onset Emery-Dreifuss muscular dystrophy (EDMD) with later involvement of 
contracture and limb-girdle muscular dystrophy type 1B is often delayed due to heterogeneous 
clinical presentations. We aimed to determine the clinical features that contribute to a delayed 
diagnosis.
Methods  We reviewed four patients who were recently diagnosed with LMNA-associated 
muscular dystrophy by targeted exome sequencing and who were initially diagnosed with non-
specific or other types of muscular dystrophy.
Results  Certain clinical features such as delayed contracture involvement and calf hypertro-
phy were found to contribute to a delayed diagnosis. Muscle biopsies were not informative for 
the diagnosis in these patients.
Conclusions  Genetic testing of single or multiple genes is useful for confirming a diagnosis of 
LMNA-associated muscular dystrophy. Even EDMD patients could experience the later involve-
ment of contracture, so clinicians should consider early genetic testing for patients with undiag-
nosed muscular dystrophy or laminopathy.
Key Words   lamin A/C, limb-girdle muscular dystrophy type 1B, emery-dreifuss muscular 
dystrophy.
Early-Onset LMNA-Associated Muscular Dystrophy 
with Later Involvement of Contracture
INTRODUCTION
LMNA-related muscular dystrophy is a rare disease with variable myopathic phenotypes 
and for which a causative mutation in the lamin A/C gene (LMNA) has been identified.1 
Emery-Dreifuss muscular dystrophy (EDMD) has been known as a phenotype of LMNA-as-
sociated muscular dystrophy disorders, along with limb-girdle muscular dystrophy type 1B 
(LGMD1B) and LMNA-related congenital muscular dystrophy (L-CMD). EDMD is charac-
terized by a clinical triad of early contracture, humeroperoneal distribution of muscle weak-
ness, and cardiac conduction block.2 EDMD symptoms typically present in childhood, and 
can appear before the age of 2 years.3 Diagnosing early-onset EDMD is challenging because 
the characteristic muscle weakness pattern and contracture do not appear definitively when 
the first symptoms appear. Moreover, histopathologic findings in LMNA-related muscular 
dystrophy are known to show nonspecific myopathic changes such as size variations in mus-
cle fibers, increased internal nuclei, and type 1 fiber predominance without dominant dys-
trophic patterns.4 
While the clinical manifestations of LGMD1B often overlap with those of EDMD, some 
features can be used to differentiate the two phenotypes. Contracture involvement is not an 
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early sign and is often mild in LGMD1B.5 The pattern of mus-
cle involvement is also milder in LGMD1B, with a proximal 
limb-girdle distribution and distal leg weakness. Delayed di-
agnosis is more common in LGMD1B patients due to the lat-
er involvement of contracture.6 Nonspecific symptoms in 
childhood also often complicate the ability to differentiate LG-
MD1B from other types of limb-girdle muscular dystrophy.
Due to cardiac and pulmonary involvement in the disease 
course of laminopathy, early diagnosis and periodic cardiac 
evaluation are important for preventing life-threatening 
complications. These risks have led to recent studies recom-
mending early genetic tests including exome sequencing in 
patients with undiagnosed and suspected muscular dystro-
phy with contracture.7,8 In addition, consecutive neurologic 
examinations should be emphasized to monitor the involve-
ment of additional symptoms. However, due to the benign 
progression of muscle weakness, undiagnosed laminopathy pa-
tients are likely to be lost in follow-up, thus reducing the proba-
bility of periodic cardiac evaluation.
In this study, we reviewed four patients who were diag-
nosed with other types of muscular dystrophy or unspecified 
myopathy at first symptom presentation between the ages of 
2 and 5 years, but who were recently rediagnosed with LM-
NA-associated muscular dystrophy by genetic screening. We 
evaluated the factors that hindered the early clinical diagnosis 
in these patients.
METHODS
Patient selection and LMNA mutation detection
We recently performed targeted sequencing of 69 selected 
genes associated with myopathy in the idiopathic muscular 
dystrophy patient cohort in our hospital.9 Patients were se-
lected by applying the following inclusion criteria: 1) muscular 
dystrophy, congenital myopathy, congenital muscular dystro-
phy, metabolic myopathy, or distal myopathy based primarily 
on clinical phenotypes and secondarily on pathologic find-
ings (if available), 2) genetically undetermined myopathy, and 
3) availability of blood or muscle samples. Genomic DNA 
was extracted from either blood or muscle. A customized 
panel containing all coding exons and exon–intron junctions 
of 69 genes that are known to be responsible for myopathy 
was used, and LMNA and emerin gene (EMD) were included. 
Sequencing was performed on the HiSeq 2000 Sequencing 
platform (Illumina, San Diego, CA, USA) platform. Sequenc-
ing data were analyzed using an in-house analysis pipeline. All 
participants had previously signed an informed-consent form 
to participate in genetic analysis.
Clinical and histopathologic assessments 
Four patients with LMNA-associated muscular dystrophy were 
included in this study and were confirmed as having an LMNA 
mutation. The applied variant calling methods were docu-
mented previously,9 and validation was performed using 
Sanger sequencing, for which the concordance rate was 96.3%. 
We then reviewed the clinical manifestations and findings of 
neurologic examinations, electromyography, and muscle biop-
sies from the other hospitals, and compared them with re-
evaluation findings from our hospital.
RESULTS
Clinical manifestations
Clinical characteristics and laboratory findings of the sub-
jects are presented in Table 1. Four patients who were con-
firmed as having LMNA mutations visited other hospitals 
when their first symptom of slow gait speed or waddling gait 
occurred between the ages of 2 and 5 years. The presence of 
contracture was not definitive at the time of the first neuro-
logic examination. Two patients (patients 3 and 4) showed 
hypertrophy of the gastrocnemius muscles. Sequencing of 
the dystrophin gene was performed in two patients (patients 
2 and 3), who were both negative for mutation in that gene. 
Without follow-up neurologic examination or evaluation, 
the patients were admitted to our hospital due to progression 
of weakness (patient 1 at age 29 years), palpitation (patient 2 
at age 29 years), scoliosis surgery (patient 3 at age 15 years), 
or for re-evaluation (patient 4 at age 11 years). In contrast to 
their first admission, all of the patients showed prominent 
proximal muscle weakness and various degrees of distal weak-
ness. All patients showed contracture in the ankle, whereas in-
volvement of the neck extensor was prominent in two patients 
(patients 1 and 4). 
Two patients had scoliosis (patients 1 and 3), and one pa-
tient had received an Achilles-tendon-lengthening operation 
(patient 4). None of the family members had any history of 
muscle weakness or gait disturbance. The serum creatine ki-
nase level was slightly elevated, ranging between 306 and 
806 U/L. Electromyography studies were conducted in three 
patients (patients 1, 2, and 4), and they showed nonspecific 
generalized myopathic patterns with low-amplitude, poly-
phasic motor unit action potentials, and early recruitment 
patterns. Cardiac evaluation including 24-hour Holter moni-
toring and echocardiography showed a cardiac conduction 
block but normal cardiac function in three patients (patients 
1, 2, and 3). Three patients had a vital capacity of around 50% 
of the predicted value, and one of them (patient 3) was using 
noninvasive positive-pressure ventilation. In one patient (pa-
tient 1), CT scans of the lower extremities showed symmetric 
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fatty atrophic changes in proximal and distal leg muscles. 
Genetic mutations
We identified a total of four LMNA mutations. The c.1357C 
>T (patient 1), c.746G>A (patient 3), and c.1583C>G (pa-
tient 4) mutations had been previously reported in EDMD 
patients, while the c.1366A>G mutation found in patient 2 
had only been reported in one L-CMD patient.10 Among 
these mutations, c.746G>A was previously reported in one 
Korean patient,11 and c.1357C>T has been reported in Chi-
nese patients.12
Histopathologic findings 
Three patients (patients 1, 2, and 3) had undergone their first 
muscle biopsy at other hospitals when their first symptoms 
occurred, but the samples were not available. Since all of the 
patients had received a muscle biopsy when they were admit-
ted to our hospital, we reviewed their pathologic records 
from other hospitals and compared them with the findings 
from the second muscle biopsy at our hospital. The patholog-
ic findings are presented in Table 2. Nonspecific myopathic 
changes such as size variations in muscle fibers, increased in-
ternal nuclei, and hypertrophic fibers with fiber splitting were 
the main features evident in the patients. Although a few de-
generative fibers were observed in patient 1, suggesting mus-
cular dystrophy, they were still nonspecific dystrophic findings 
(Fig. 1). The findings of immunohistochemistry investiga-
tions using antibodies to lamin A/C and emerin were normal 
compared to healthy controls (Fig. 2). 
Table 1. Clinical and laboratory findings
Patient number
1 2 3 4
Age at onset (years) 4 5 2 3
Age at diagnosis (years) 29 29 15 11
Sex Male Male Male Female
Family history None None None None
Initial symptoms
Weakness in both legs, and 
slow gait 
Waddling gait Weakness in both legs Slow gait
Muscle strength (MRC grade)
Neck: G3
U/Ex: G4
L/Ex: G4
Neck: G5
U/Ex: G4
L/Ex: G4
Neck: G5
U/Ex: G4
L/Ex: G4
Neck: G5
U/Ex: G4
L/Ex: G4
Contracture Neck and ankle Elbow and ankle Elbow, knee, and ankle Neck and ankle
Scoliosis + – + –
Pseudohypertrophy – – + +
Clinical phenotype EDMD LGMD1B LGMD1B EDMD
CK level (U/L) 306 806 518 411
ECG First-degree AV block Atrial fibrillation and RBBB RBBB Normal sinus rhythm
EMG Myopathy Not done Myopathy Myopathy
Vital capacity (percentage of 
  predicted value, %)
57 57 56 84
Current status Independent gait Walking with assistance Wheelchair ambulation Independent gait
Mutation c.1357C>T c.1366A>G c.746G>A c.1583C>G
AV: atrioventricular, CK: creatine kinase, ECG: electrocardiography, EDMD: Emery-Dreifuss muscular dystrophy, EMG: electromyography, L/Ex: lower ex-
tremities, LGMD1B: limb-girdle muscular dystrophy type 1B, MRC: Medical Research Council, RBBB: right bundle branch block, U/Ex: upper extremi-
ties.
Table 2. Histopathologic findings of muscle biopsies
Patient 
number
Biopsy site
Age at biopsy 
(years)
Fiber size 
variation
Necrotic 
fibers
Hypertrophic 
fibers
Internal 
nuclei
Perimysial 
fibrosis
Emerin 
staining
Lamin A/C 
staining
1   Biceps brachii 29 Mild + – – – Normal Normal
2   Vastus lateralis 29 Moderate – + – – Normal Normal
3   Intercostal muscle 15 Moderate – + + + Normal Normal
4   Not available 11 Moderate  – + + + Normal Normal
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DISCUSSION
The four patients in this study had clinical phenotypes of 
EDMD or LGMD1B with known mutations in LMNA. 
Symptom onset had occurred during early childhood be-
tween the ages of 2 and 5 years. The patients had no common 
features of L-CMD, including infantile onset, delayed devel-
opment, dropped head syndrome, or inflammatory histopath-
ologic changes.10,13 They were initially diagnosed with nonspe-
cific myopathy or other types of muscular dystrophy based 
on both clinical manifestations and pathologic findings. How-
ever, when the patients were admitted to our hospital as ado-
lescents or adults, they showed the typical clinical features of 
LMNA-associated muscular dystrophy, including progressive 
proximal muscle weakness with joint contracture and the in-
volvement of cardiac conduction block. 
Diagnosing LMNA-associated muscular dystrophy is known 
to be challenging in the limb-girdle muscular dystrophy phe-
notype due to the lack of suggestive clinical features. Although 
the distribution of muscle weakness in patients with LMNA 
mutations can be divided into limb-girdle and humeropero-
neal types, which are phenotypes of LGMD1B and EDMD, 
respectively, the pattern of muscle involvement often over-
laps between the two types. Moreover, early contracture of-
ten occurring before muscle weakness is common in EDMD, 
whereas contracture appears later in LGMD1B and is less se-
vere. 
In this study, we found that several clinical factors con-
tributed to the delayed diagnosis of LMNA-associated mus-
cular dystrophy. First, there was later involvement of con-
tracture in early-onset EDMD and LGMD1B patients. It has 
previously been suggested that later and mild involvement of 
contracture in LGMD1B contribute to its delayed diagnosis.6 
Although early contracture often occurring before muscle 
weakness is a characteristic feature of EDMD, contracture can 
appear after weakness with a delay of up to 7 years.3 Although 
elbow contracture has previously been suggested as an early 
diagnostic marker,6 we found that most of the patients in our 
study cohort showed prominent ankle involvement. 
Second, patients with calf hypertrophy with prominent 
proximal weakness were diagnosed as having other types of 
muscular dystrophy. Calf hypertrophy is known to more of-
ten be suggestive of Becker muscular dystrophy and LGM-
D2I.7 Consortium guidelines published in 1991 suggested the 
presence of marked calf hypertrophy as an exclusion criterion 
for X-linked EDMD patients.14 However, as reported previ-
Fig. 1. Histopathologic findings of a muscle biopsy. A, B, and C: A muscle biopsy specimen from patient 1 showed slight size variations in the muscle 
fibers and a few necrotic and degenerative fibers, suggesting mild myopathic changes. D: Emerin protein was detectable. A: Hematoxylin and eo-
sin stain (×200), B: NADH stain (×200), C: modified Gomori trichrome stain (×200), D: Emerin immunohistochemistry (×200).
A  
C  
B  
D  
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ously,3 calf hypertrophy can be observed in laminopathy.
Third, patient education about muscle contracture was not 
emphasized. A previous study suggested that the involve-
ment of the neck extensor and elbow contracture were the 
clinical features that were most helpful for an early diagnosis 
of laminopathy.6 Because muscle weakness is slowly progres-
sive in laminopathy, these patients were not referred to neu-
rologists, and the importance of additional features of muscu-
lar dystrophy were not recognized. This resulted in three of the 
patients receiving tendon-lengthening surgery or a scoliosis 
operation without visiting neurology clinics. 
Three of the four patients underwent muscle biopsies at 
two different times, with 13 to 25 years between the first and 
second procedures. Serial histopathologic results from the 
two biopsies showed nonspecific myopathic changes, and the 
immunostaining of lamin A/C and emerin appeared normal 
compared to healthy controls. This shows that serial follow-
up muscle biopsies were not informative for the diagnosis in 
these patients even during the progressive stage of laminopa-
thy. Because of this finding, muscle biopsies are recommend-
ed for patients with negative genetic tests.7 
The LMNA mutations identified in these patients had been 
previously reported in EDMD, but the c.1366A>G mutation 
detected in patient 2 had only been reported once in an L-
CMD patient. One of the present patients had a clinical pheno-
type of LGMD1B and reported that symptom onset had oc-
curred at the age of 3 years without dropped head syndrome, 
which represents the first report of this mutation in an LGM-
D1B patient. 
One study found laminopathy in 4 of 116 congenital mus-
cular dystrophy patients,15 and the application of high-
throughput sequencing to patients who were considered to 
have an unspecified myopathy recently revealed LMNA-asso-
ciated muscular dystrophy in 5 of 36 patients.12 Even though 
this is a rare cause of muscular dystrophy, clinicians should 
consider the possibility of laminopathy and conduct early 
genetic testing in undiagnosed muscular dystrophy patients 
with limb-girdle weakness, early humeroperoneal weakness, 
contracture, or cardiomyopathy due to the possibility of life-
threatening cardiac and pulmonary complications.7 
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